# Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

> **NCT01484600** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** REGN668: Injection Rate 1
- **DRUG:** REGN668: Injection Rate 2

## Key facts

- **NCT ID:** NCT01484600
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484600, "Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01484600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*